Inflammatory cardiomyopathy: A current view on the pathophysiology, diagnosis, and treatment

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Krejci, Jan ^a,b   Mlejnek, Dalibor ^a,b   Sochorova, Dana ^b   Nemec, Petr ^b,c  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c CENTRE FOR CARDIOVASCULAR SURGERY AND TRANSPLANTATION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TELBIVUDINE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ANTIMICROBIAL THERAPY; CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CORONARY ANGIOGRAPHY; DEVICE THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE BIOPSY; HUMAN; INFLAMMATORY CARDIOMYOPATHY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; THORAX PAIN; VIRUS INFECTION; BIOPSY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHIES; EVIDENCE BASED MEDICINE; PROCEDURES; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOPSY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHIES; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDITIS; TREATMENT OUTCOME;

EID: 84976630300     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/4087632     Document Type: Review

References (106)

1. P. Richardson, R. W. McKenna, M. Bristow et al., "Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies," Circulation, vol. 93, no. 5, pp. 841-842, 1996.
2. A. L. P. Caforio, S. Pankuweit, E. Arbustini et al., "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases," European Heart Journal, vol. 34, no. 33, pp. 2636-2648, 2013.
3. G. Hufnagel, S. Pankuweit, A. Richter, U. Schönian, and B. Maisch, "The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results," Herz, vol. 25, no. 3, pp. 279-285, 2000.
4. J. P. Breinholt, M. Moulik, W. J. Dreyer et al., "Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients," Journal of Heart and Lung Transplantation, vol. 29, no. 7, pp. 739-746, 2010.
5. B. Maisch and S. Pankuweit, "Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy," Herz, vol. 37, no. 6, pp. 644-656, 2012.
6. L. H. Malik, G. D. Singh, and E. A. Amsterdam, "The epidemiology, clinical manifestations, and management of chagas heart disease," Clinical Cardiology, vol. 38, no. 9, pp. 565-569, 2015.
7. T. Palecek, P. Kuchynka, D. Hulinska et al., "Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy," Medical Microbiology and Immunology, vol. 199, no. 2, pp. 139-143, 2010.
8. M. Kubánek, M. Sramko, D. Berenová et al., "Detection of Borrelia burgdorferi sensu lato in endomyocardial biopsy specimens in individuals with recent-onset dilated cardiomyopathy," European Journal of Heart Failure, vol. 14, no. 6, pp. 588-596, 2012.
9. L. T. Cooper Jr., "Myocarditis," The New England Journal of Medicine, vol. 360, no. 15, pp. 1526-1538, 2009.
10. I. Kindermann, C. Barth, F. Mahfoud et al., "Update on myocarditis," Journal of the American College of Cardiology, vol. 59, no. 9, pp. 779-792, 2012.
11. R. Dennert, H. J. Crijns, and S. Heymans, "Acute viralmyocarditis," EuropeanHeart Journal, vol. 29, no. 17, pp. 2073-2082, 2008.
12. M. Noutsias, M. Pauschinger, W.-C. Poller, H.-P. Schultheiss, and U. Kühl, "Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy," Heart Failure Monitor, vol. 3, no. 4, pp. 127-135, 2003.
13. A. L. P. Caforio, S. Bottaro, and S. Iliceto, "Dilatedcardiomyopathy (DCM) andmyocarditis: classification, clinical and autoimmune features," Applied Cardiopulmonary Pathophysiology, vol. 16, no. 1, pp. 82-95, 2012.
14. C. Wehlou and J. R. Delanghe, "Detection of antibodies in cardiac autoimmunity," Clinica Chimica Acta, vol. 408, no. 1-2, pp. 114-122, 2009.
15. A. L. P. Caforio, N. J. Mahon, F. Tona, and W. J. McKenna, "Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance," European Journal of Heart Failure, vol. 4, no. 4, pp. 411-417, 2002.
16. N. R. Rose, "Myocarditis: infection versus autoimmunity," Journal of Clinical Immunology, vol. 29, no. 6, pp. 730-737, 2009.
17. H.-P. Schultheiss, U. Khl, and L. T. Cooper, "Themanagementof myocarditis," European Heart Journal, vol. 32, no. 21, pp. 2616-2625, 2011.
18. A. DAmbrosio, G. Patti, A. Manzoli et al., "The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review," Heart, vol. 85, no. 5, pp. 499-504, 2001.
19. A. L. P. Caforio, R. Marcolongo, C. Basso, and S. Iliceto, "Clinical presentation and diagnosis of myocarditis," Heart, vol. 101, no. 16, pp. 1332-1344, 2015.
20. J. W. Mason, J. B. OConnell, A. Herskowitz et al., "A clinical trial of immunosuppressive therapy for myocarditis," The New England Journal of Medicine, vol. 333, no. 5, pp. 269-275, 1995.
21. U. Kühl, M. Pauschinger, M. Noutsias et al., "High prevalence of viral genomes and multiple viral infections in the myocardium of adults with idiopathic left ventricular dysfunction," Circulation, vol. 111, no. 7, pp. 887-893, 2005.
22. J. Krejcí, H. Poloczková, P. Hude et al., "Impact of inflammatory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters," Cor et Vasa, vol. 55, no. 4, pp. e333-e340, 2013.
23. U. Kühl, "Antiviral treatment of myocarditis and acute dilated cardiomyopathy,"Heart Failure Clinics, vol. 1, no. 3, pp. 467-474, 2005.
24. F. Kuethe, J. Lindner, K. Matschke et al., "Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis," Clinical Infectious Diseases, vol. 49, no. 11, pp. 1660-1666, 2009.
25. F. Escher, S. Modrow, T. Sabi et al., "Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy," Medical Science Monitor, vol. 14, no. 12, pp. CR589-CR597, 2008.
26. S. A. Koepsell, D. R. Anderson, and S. J. Radio, "Parvovirus B19 is a bystander in adult myocarditis," Cardiovascular Pathology, vol. 21, no. 6, pp. 476-481, 2012.
27. G. C. Stewart, J. Lopez-Molina, R. V. S. R. K. Gottumukkala et al., "Myocardial Parvovirus B19 persistence: lack of association with clinicopathologic Phenotype in adults with heart failure," Circulation: Heart Failure, vol. 4, no. 1, pp. 71-78, 2011.
28. A. L. P. Caforio, F. Calabrese, A. Angelini et al., "A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis," European Heart Journal, vol. 28, no. 11, pp. 1326-1333, 2007.
29. U. Kühl, D. Lassner, J. von Schlippenbach, W. Poller, and H.-P. Schultheiss, "Interferon-beta improves survival in enterovirusassociated cardiomyopathy," Journal of the American College of Cardiology, vol. 60, no. 14, pp. 1295-1296, 2012.
30. I. Kindermann, M. Kindermann, R. Kandolf et al., "Predictors of outcome in patients with suspectedmyocarditis," Circulation, vol. 118, no. 6, pp. 639-648, 2008.
31. C.-T. Bock, K. Klingel, and R. Kandolf, "Humanparvovirus B19-associated myocarditis," New England Journal of Medicine, vol. 362, no. 13, pp. 1248-1249, 2010.
32. S. Pankuweit and K. Klingel, "Viral myocarditis: from experimentalmodels to molecular diagnosis in patients,"Heart Failure Reviews, vol. 18, no. 6, pp. 683-702, 2013.
33. C. T. Bock, A. Düchting, and F. Utta, "Molecular phenotypes of human parvovirus B19 in patients with myokarditis," World Journal of Cardiology, vol. 6, pp. 183-195, 2014.
34. D. Lassner, M. Rohde, C. S. Siegismund et al., "Myocarditis-personalized medicine by expanded endomyocardial biopsy diagnostics," World Journal of Cardiovascular Diseases, vol. 4, no. 6, pp. 325-340, 2014.
35. D. Fairweather, L. T. Cooper Jr., and L. A. Blauwet, "Sex and gender differences in myocarditis and dilated cardiomyopathy," Current Problems in Cardiology, vol. 38, no. 1, pp. 7-46, 2013.
36. R. E. McCarthy III, J. P. Boehmer, R. H. Hruban et al., "Longterm outcome of fulminant myocarditis as compared with acute (nonfulminant)myocarditis,"The New England Journal of Medicine, vol. 342, no. 10, pp. 690-695, 2000.
37. J. Krejci, P. Hude, H. Poloczkova et al., "Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy," Heart and Vessels, vol. 31, pp. 416-426, 2016.
38. C. Tschöpe, C.-T. Bock, M. Kasner et al., "High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction," Circulation, vol. 111, no. 7, pp. 879-886, 2005.
39. H. Baccouche, H. Mahrholdt, G. Meinhardt et al., "Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease," European Heart Journal, vol. 30, no. 23, pp. 2869-2879, 2009.
40. J. Krejci, P. Hude, L. Spinarova et al., "The variable clinical course of peripartum cardiomyopathy," Biomedical Papers, vol. 158, no. 1, pp. 92-97, 2014.
41. B. D. Bültmann, K. Klingel, M. Näbauer, D. Wallwiener, and R. Kandolf, "High prevalence of viral genomes and inflammation in peripartum cardiomyopathy," American Journal of Obstetrics and Gynecology, vol. 193, no. 2, pp. 363-365, 2005.
42. M. G. Midei, S. H. DeMent, A. M. Feldman, G. M. Hutchins, and K. L. Baughman, "Peripartum myocarditis and cardiomyopathy," Circulation, vol. 81, no. 3, pp. 922-928, 1990.
43. K. Sliwa, D. Hilfiker-Kleiner, M. C. Petrie et al., "Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy," European Journal of Heart Failure, vol. 12, no. 8, pp. 767-778, 2010.
44. L. A. Blauwet and L. T. Cooper, "Diagnosis and management of peripartum cardiomyopathy," Heart, vol. 97, no. 23, pp. 1970-1981, 2011.
45. M. B. Gentry, J. K. Dias, A. Luis, R. Patel, J. Thornton, and G. L. Reed, "African-American women have a higher risk for developing Peripartum cardiomyopathy," Journal of the American College of Cardiology, vol. 55, no. 7, pp. 654-659, 2010.
46. L. T. Cooper, P. J. Mather, J. D. Alexis et al., "Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women," Journal of Cardiac Failure, vol. 18, no. 1, pp. 28-33, 2012.
47. A. M. Amos, W. A. Jaber, and S. D. Russell, "Improvedoutcomes in peripartum cardiomyopathy with contemporary," American Heart Journal, vol. 152, no. 3, pp. 509-513, 2006.
48. J. G. Safirstein, A. S. Ro, S. Grandhi, L. Wang, J. D. Fett, and C. Staniloae, "Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet," International Journal of Cardiology, vol. 154, no. 1, pp. 27-31, 2012.
49. J. Krejci, H. Poloczkova, and P. Nemec, "Current therapeutic concepts in peripartum cardiomyopathy," Current Pharmaceutical Design, vol. 21, no. 4, pp. 507-514, 2015.
50. M. G. Friedrich, U. Sechtem, J. Schulz-Menger et al., "Cardiovascular magnetic resonance in myocarditis: a JACC White Paper," Journal of theAmericanCollege of Cardiology, vol. 53, no. 17, pp. 1475-1487, 2009.
51. M. A. G. M. Olimulder, J. van Es, and M. A. Galjee, "The importance of cardiac MRI as a diagnostic tool in viral myocarditisinduced cardiomyopathy,"NetherlandsHeart Journal, vol. 17, no. 12, pp. 481-486, 2009.
52. O. Bruder, A. Wagner, M. Lombardi et al., "European Cardiovascular Magnetic Resonance (EuroCMR) registry-multi national results from 57 centers in 15 countries," Journal of Cardiovascular Magnetic Resonance, vol. 15, article 9, 2013.
53. P. Lurz, I. Eitel, J. Adam et al., "Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis," JACC Cardiovascular Imaging, vol. 5, no. 5, pp. 513-524, 2012.
54. P. Kuchynka, T. Palecek, E. Nemecek, M. Fikrle, and A. Linhart, "New therapeutic aspects on inflammatory cardiomyopathy," Current Pharmaceutical Design, vol. 21, no. 4, pp. 459-465, 2015.
55. S. Grün, J. Schumm, S. Greulich et al., "Long-term followup of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery," Journal of the American College of Cardiology, vol. 59, no. 18, pp. 1604-1615, 2012.
56. M. Francone, C. Chimenti, N. Galea et al., "CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis," JACC Cardiovascular Imaging, vol. 7, no. 3, pp. 254-263, 2014.
57. B. Lauer, C. Niederau, U. Kühl et al., "Cardiac troponin T in patients with clinically suspected myocarditis," Journal of the American College of Cardiology, vol. 30, no. 5, pp. 1354-1359, 1997.
58. C. Ukena, M. Kindermann, F. Mahfoud et al., "Diagnostic and prognostic validity of different biomarkers in patients with suspectedmyocarditis," Clinical Research in Cardiology, vol. 103, no. 9, pp. 743-751, 2014.
59. A. Frustaci, C. Chimenti, F. Calabrese, M. Pieroni, G. Thiene, and A. Maseri, "Immunosuppressive therapy for active lymphocytic myocarditis. Virological and immunologic profile of responders versus nonresponders," Circulation, vol. 107, no. 6, pp. 857-866, 2003.
60. F. Mahfoud, B. Grtner, M. Kindermann et al., "Virus serology in patients with suspected myocarditis: utility or futility?" European Heart Journal, vol. 32, no. 7, pp. 897-903, 2011.
61. B. Heidecker, M. M. Kittleson, E. K. Kasper et al., "Transcriptomic biomarkers for the accurate diagnosis of myocarditis," Circulation, vol. 123, no. 11, pp. 1174-1184, 2011.
62. L. T. Cooper Jr., O. K. Onuma, S. Sagar et al., "Genomic and proteomic analysis ofmyocarditis and dilated cardiomyopathy," Heart Failure Clinics, vol. 6, no. 1, pp. 75-85, 2010.
63. M. F. Corsten, A. Papageorgiou, W. Verhesen et al., "MicroRNA profiling identifies MicroRNA-155 as an adverse mediator of cardiac injury and dysfunction during Acute Viral MyoCarditis," Circulation Research, vol. 111, no. 4, pp. 415-425, 2012.
64. J.-L. Bao and L. Lin, "MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-κB pathway during acute viral myocarditis," European Review forMedical and Pharmacological Sciences, vol. 18, no. 16, pp. 2349-2356, 2014.
65. U. Kühl, M. Rohde, D. Lassner, U. M. Gross, F. Escher, and H.-P. Schultheiss, "miRNAas activitymarkers in Parvo B19 associated heart disease," Herz, vol. 37, no. 6, pp. 637-643, 2012.
66. U. Kühl, D. Lassner, A. Dorner et al., "Adistinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression," Basic Research in Cardiology, vol. 108, article 372, 2013.
67. F. Escher, D. Lassner, U. Kühl et al., "Analysis of endomyocardial biopsies in suspected myocarditis-diagnostic value of left versus right ventricularbiopsy," International Journal of Cardiology, vol. 177, no. 1, pp. 76-78, 2014.
68. A. Yilmaz, I. Kindermann, M. Kindermann et al., "Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance," Circulation, vol. 122, no. 9, pp. 900-909, 2010.
69. C. Chimenti and A. Frustaci, "Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period," Circulation, vol. 128, no. 14, pp. 1531-1541, 2013.
70. H. T. Aretz, M. E. Billingham, W. D. Edwards et al., "Myocarditis. A histopathologic definition and classification," The American Journal of Cardiovascular Pathology, vol. 1, no. 1, pp. 3-14, 1987.
71. K. L. Baughman, "Diagnosis of myocarditis: death of Dallas criteria," Circulation, vol. 113, no. 4, pp. 593-595, 2006.
72. U. Kühl, M. Noutsias, B. Seeberg, and H.-P. Schultheiss, "Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy," Heart, vol. 75, no. 3, pp. 295-300, 1996.
73. L. T. Cooper, K. L. Baughman, A. M. Feldman et al., "The role of endomyocardial biopsy in themanagement of cardiovascular disease: a scientific statement fromthe American Heart Association, the American College of Cardiology, and the European Society of Cardiology," Circulation, vol. 116, no. 19, pp. 2216-2233, 2007.
74. A. M. From, J. J. Maleszewski, and C. S. Rihal, "Current status of endomyocardial biopsy,"Mayo Clinic Proceedings, vol. 86, no. 11, pp. 1095-1102, 2011.
75. G. Thiene, P. Bruneval, J. Veinot, and O. Leone, "Diagnostic use of the endomyocardial biopsy: a consensus statement," Virchows Archiv, vol. 463, no. 1, pp. 1-5, 2013.
76. B. Maisch, I. Portig, A. Ristic, G. Hufnagel, and S. Pankuweit, "Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus: a status report," Herz, vol. 25, no. 3, pp. 200-209, 2000.
77. A. Frustaci, M. A. Russo, and C. Chimenti, "Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study," European Heart Journal, vol. 30, no. 16, pp. 1995-2002, 2009.
78. F. Escher, U. Kühl, D. Lassner et al., "Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome," European Journal of Heart Failure, vol. 16, no. 10, pp. 1066-1072, 2014.
79. R. Wojnicz, E. Nowalany-Kozielska, C. Wojciechowska et al., "Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Twoyear follow-up results," Circulation, vol. 104, no. 1, pp. 39-45, 2001.
80. L. H. Chow, S. J. Radio, T. D. Sears, and B. M. Mcmanus, "Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis," Journal of the American College of Cardiology, vol. 14, no. 4, pp. 915-920, 1989.
81. A. J. Hauck, D. L. Kearney, and W. D. Edwards, "Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error," Mayo Clinic Proceedings, vol. 64, no. 10, pp. 1235-1245, 1989.
82. J. J. V. McMurray, S. Adamopoulos, S. D. Anker et al., "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC," European Heart Journal, vol. 33, no. 14, pp. 1787-1847, 2012.
83. C. W. Yancy, M. Jessup, B. Bozkurt et al., "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines," Circulation, vol. 128, no. 16, pp. e240-e327, 2013.
84. T. J. Bahk, M. D. Daniels, J. S. Leon, K. Wang, and D. M. Engman, "Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis," International Journal of Cardiology, vol. 125, no. 1, pp. 85-93, 2008.
85. S. Saegusa, Y. Fei, T. Takahashi et al., "Oral administration of candesartan improves the survival of mice with viralmyocarditis through modification of cardiac adiponectin expression," Cardiovascular Drugs and Therapy, vol. 21, no. 3, pp. 155-160, 2007.
86. Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto, "Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property," American Journal of Physiology-Heart and Circulatory Physiology, vol. 286, no. 1, pp. H83-H90, 2004.
87. M. Pauschinger, S. Rutschow, K. Chandrasekharan et al., "Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis: association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated immune response," European Journal of Heart Failure, vol. 7, no. 4, pp. 444-452, 2005.
88. J. Xiao, M. Shimada, W. Liu, D. Hu, and A. Matsumori, "Anti-inflammatory effects of eplerenone on viral myocarditis," European Journal of Heart Failure, vol. 11, no. 4, pp. 349-353, 2009.
89. L. T. Cooper Jr., G. J. Berry, and R. Shabetai, "Idiopathic giant-cell myocarditis-natural history and treatment," The New England Journal of Medicine, vol. 336, no. 26, pp. 1860-1866, 1997.
90. L. T. Cooper Jr., J. M. Hare, H. D. Tazelaar et al., "Usefulness of immunosuppression for giant cell myocarditis," American Journal of Cardiology, vol. 102, no. 11, pp. 1535-1539, 2008.
91. R. Kandolin, J. Lehtonen, K. Salmenkivi, A. Räisänen-Sokolowski, J. Lommi, and M. Kupari, "Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression," Circulation: Heart Failure, vol. 6, no. 1, pp. 15-22, 2013.
92. S. Kawano, J. Kato, N. Kawano et al., "Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period," Internal Medicine, vol. 50, no. 9, pp. 975-981, 2011.
93. T. Yanagisawa, T. Inomata, I. Watanabe et al., "Clinical significance of corticosteroid therapy for eosinophilic myocarditis," International Heart Journal, vol. 52, no. 2, pp. 110-113, 2011.
94. L. A. Blauwet and L. T. Cooper, "Idiopathic giant cellmyocarditis and cardiac sarcoidosis," Heart Failure Reviews, vol. 18, no. 6, pp. 733-746, 2013.
95. A. Frustaci and C. Chimenti, "Immunosuppressive therapy in myocarditis," Circulation Journal, vol. 79, no. 1, pp. 4-7, 2014.
96. C. Stanton, F. Mookadam, S. Cha et al., "Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy," International Journal of Cardiology, vol. 128, no. 1, pp. 38-41, 2008.
97. C. Lu, F. Qui, Y. Yan, T. Liu, J. Li, and H. Chen, "Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials," Journal of CardiovascularMedicine, 2014.
98. J. W. Mason, J. B. OConnell, A. Herskowitz et al., "A clinical trial of immunosuppressive therapy for myocarditis," The New England Journal of Medicine, vol. 333, no. 5, pp. 269-275, 1995.
99. T. Palecek, J. Krejci, L. Pecen et al., "Czech Inflammatory Cardiomyopathy Immunosuppression Trial (CZECH-ICIT): randomized, multicentric study comparing the effect of two regimens of combined immunosuppressive therapy in the treatment of inflammatory cardiomyopathy: the aims and design of the trial," Cor et Vasa, vol. 55, no. 6, pp. e475-e478, 2013.
100. L. Gullestad, H. Aass, J. G. Fjeld et al., "Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure," Circulation, vol. 103, no. 2, pp. 220-225, 2001.
101. R. Dennert, S. Velthuis, S. Schalla et al., "Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load," AntiviralTherapy, vol. 15, no. 2, pp. 193-201, 2010.
102. D. M. McNamara, R. Holubkov, R. C. Starling et al., "Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy," Circulation, vol. 103, no. 18, pp. 2254-2259, 2001.
103. A. Staudt, A. Hummel, J. Ruppert et al., "Immunoadsorption in dilated cardiomyopathy: 6-month results froma randomized study," American Heart Journal, vol. 152, no. 4, pp. 712. e1-712. e6, 2006.
104. S. B. Felix, A. Staudt, and W. V. Dörffer, "Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study," Journal of the American College of Cardiology, vol. 35, no. 6, pp. 1590-1598, 2000.
105. U. Kühl, M. Pauschinger, P. L. Schwimmbeck et al., "Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction," Circulation, vol. 107, no. 22, pp. 2793-2798, 2003.
106. O. Zimmermann, C. Rodewald, M. Radermacher et al., "Interferon β-1b therapy in chronic viral dilated cardiomyopathy-is there a role for specific therapy?" Journal of Cardiac Failure, vol. 16, no. 4, pp. 348-356, 2010.